{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:41:47Z","timestamp":1786466507652,"version":"build-2736575974"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Hosp Pharm"],"abstract":"<jats:p>Background: Venous thromboembolism (VTE) events occur in association with COVID-19, and the optimal duration of anticoagulant treatment is uncertain.\nObjectives: The primary objectives were to determine the duration of anticoagulant prescriptions filled after COVID-19\u2013associated VTE and the proportion of patients experiencing VTE recurrence. The secondary objective was to determine the proportion of patients who experienced bleeding events.\nMethods: This retrospective cohort study analyzed data for cases of COVID-19\u2013associated VTE across Alberta, Canada, confirmed between February 23, 2020, and June 30, 2022. Outpatient cases of VTE were identified using codes from the International Classification of Diseases, Ninth Revision plus Alberta Health Service procedure codes. Inpatient cases of VTE and bleeding events were identified using codes from the International Classification of Diseases and Related Health Problems, 10th Revision.\nResults: Among the 822 patients included in the analysis, median follow-up was 359.0 days, with the majority of follow-up occurring while patients were off treatment (median 273.0 days). The median age was 59 years, 61.9% of the patients were male, 82.1% had a pulmonary embolism, 71.9% had not received COVID-19 vaccinations, and the median Charlson comorbidity index score was 1. The median duration of treatment was 100.0 (interquartile range 71.0\u2013190.0) days, with 360 patients (43.8%) filling their prescriptions for 0\u20133 months, 234 (28.5%) for 4\u20136 months, 181 (22.0%) for 7\u201312 months, and 47 (5.7%) for more than 12 months. Overall, recurrent VTE occurred in 49 patients (6.0%), 24 of whom had continuously filled their anticoagulant prescriptions up to the time of the event. Bleeding occurred in 72 patients (8.8%).\nConclusions: Given the prolonged follow-up period off anticoagulant treatment for most patients, it is reasonable to consider 3\u20136 months of therapy for COVID-19\u2013associated VTE.\nKeywords: anticoagulants, COVID-19, venous thromboembolism, deep vein thrombosis, pulmonary embolism\nR\u00c9SUM\u00c9\nContexte : Les \u00e9v\u00e9nements de thromboembolie veineuse (TEV) surviennent en association avec la COVID-19, et la dur\u00e9e optimale du traitement anticoagulant est incertaine.\nObjectifs : L\u2019objectif principal consistait \u00e0 d\u00e9terminer la dur\u00e9e des ordonnances d\u2019anticoagulants ex\u00e9cut\u00e9es apr\u00e8s une TEV associ\u00e9e \u00e0 la COVID-19 et la part des patients chez qui la TEV avait r\u00e9cidiv\u00e9. L\u2019objectif secondaire consistait \u00e0 d\u00e9terminer la part des patients vivant des \u00e9v\u00e9nements h\u00e9morragiques.\nM\u00e9thodologie : Cette \u00e9tude de cohorte r\u00e9trospective a analys\u00e9 les donn\u00e9es des cas de TEV associ\u00e9s \u00e0 la COVID-19 en Alberta, au Canada, confirm\u00e9s entre le 23 f\u00e9vrier 2020 et le 30 juin 2022. Les cas ambulatoires de TEV ont \u00e9t\u00e9 identifi\u00e9s \u00e0 l\u2019aide des codes de la Classification internationale des maladies, neuvi\u00e8me r\u00e9vision, ainsi que des Codes de proc\u00e9dure des Services de sant\u00e9 de l\u2019Alberta. Les hospitalisations pour TEV et les \u00e9v\u00e9nements h\u00e9morragiques ont \u00e9t\u00e9 identifi\u00e9s \u00e0 l\u2019aide des codes de la Classification internationale des maladies et des probl\u00e8mes de sant\u00e9 connexes, dixi\u00e8me r\u00e9vision.\nR\u00e9sultats : Parmi les 822 patients inclus dans l\u2019analyse, le suivi m\u00e9dian \u00e9tait de 359,0 jours, la majorit\u00e9 du suivi ayant eu lieu lorsque les patients n\u2019\u00e9taient plus sous traitement (m\u00e9dian 273,0 jours). L\u2019\u00e2ge m\u00e9dian \u00e9tait de 59 ans; 61,9 % des patients \u00e9taient des hommes; 82,1 % avaient une embolie pulmonaire; 71,9 % n\u2019avaient pas re\u00e7u de vaccination contre la COVID-19; et le score m\u00e9dian de l\u2019indice de comorbidit\u00e9 de Charlson \u00e9tait de 1. La dur\u00e9e m\u00e9diane du traitement \u00e9tait de 100 jours (\u00e9cart interquartile 71\u2013190 jours), avec 360 patients (43,8 %) ayant ex\u00e9cut\u00e9 leur prescription pendant 0 \u00e0 3 mois, 234 (28,5 %) pendant 4 \u00e0 6 mois, 181 (22,0 %) pendant 7 \u00e0 12 mois, et 47 (5,7 %) pendant plus de 12 mois. Globalement, une r\u00e9cidive de la TEV est survenue chez 49 patients (6,0 %), dont 24 avaient continuellement ex\u00e9cut\u00e9 leur ordonnance d\u2019anticoagulants jusqu\u2019\u00e0 l\u2019\u00e9v\u00e9nement. Des saignements sont survenus chez 72 patients (8,8 %).\nConclusions : \u00c9tant donn\u00e9 la dur\u00e9e prolong\u00e9e du suivi sans traitement anticoagulant pour la plupart des patients, il est raisonnable de consid\u00e9rer 3 \u00e0 6 mois de traitement pour la TEV associ\u00e9e \u00e0 la COVID-19.\nMots-cl\u00e9s : anticoagulants, COVID-19, thromboembolie veineuse, thrombose veineuse profonde, embolie pulmonaire<\/jats:p>","DOI":"10.4212\/cjhp.3702","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:45:59Z","timestamp":1786463159000},"source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 and Recurrent Venous Thromboembolism (CORE-VTE)"],"prefix":"10.4212","volume":"78","author":[{"given":"Jesalyn","family":"Clarkson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal","family":"Guirguis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy J","family":"Bungard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2732","published-online":{"date-parts":[[2025,7,9]]},"container-title":["Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3702\/5668","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3702\/5669","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3702\/5668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:45:59Z","timestamp":1786463159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/3702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,10]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.3702","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"value":"1920-2903","type":"electronic"},{"value":"0008-4123","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"article-number":"e3702"}}